Aprecia, the 3DP Pharmaceutical Company, announced today that Amol Matharu, Ph.D., has been named the company’s Chief Scientific Officer. Matharu will lead the company’s Research & Development function, the foundation for which is Aprecia’s proprietary ZipDose® Technology, the world’s first and only commercially viable 3DP technology platform and is used in the first FDA-approved 3D-printed drug.
| CINCINNATI, Jan. 30, 2020 /PRNewswire/ -- Aprecia, the 3DP Pharmaceutical Company, announced today that Amol Matharu, Ph.D., has been named the company’s Chief Scientific Officer. Matharu will lead the company’s Research & Development function, the foundation for which is Aprecia’s proprietary ZipDose® Technology, the world’s first and only commercially viable 3DP technology platform and is used in the first FDA-approved 3D-printed drug.
Matharu has more than 20 years of industry experience, which includes capability development, product innovation, product commercialization and intellectual property development in leadership roles at AMRI, Actavis, Navinta, Novartis and Sandoz. He earned his Ph.D. in Pharmaceutical Sciences from Long Island University and his MBA from MIT Sloan School of Management. His responsibilities at Aprecia will include advancing the company’s pipeline of medicines, expanding strategic partnerships, and guiding the development of proprietary forming systems that will meet future product and partner needs. “We are extremely pleased to have Amol lead Aprecia’s expanding 3DP formulation and product development team,” said Aprecia CEO, Chris Gilmore. “Amol will help accelerate Aprecia’s commitment to the research and development of entirely new precision medicines that are patient focused.” Along with the appointment of Matharu, the company’s expanded emphasis on Research & Development includes enhanced capabilities in analytical science, pharmaceutical development, and process development engineering in Aprecia’s R&D facility in East Windsor, New Jersey. Matharu plans to advance the company’s R&D initiatives with an expanded team and strategic partnerships. “Aprecia has a unique technology with tremendous potential in niche areas of ODT, high drug loading, drug delivery and complex patient types,” Matharu stated. “Additionally, I am passionate about enabling colleagues and installing high-performance teams. I’m delighted to be working with the skillful individuals at Aprecia and our world-class partners who are making precision medicine possible.” About Aprecia
SOURCE Aprecia Pharmaceuticals |
View original content to download multimedia:
